成人非体外去除单倍体相合外周血干细胞移植中抗胸腺细胞球蛋白靶向给药:一项单臂2期试验
本研究在成人非体外去除单倍体相合外周血干细胞移植中建立基于抗胸腺细胞球蛋白(ATG)浓度监测的靶向给药策略,2期试验纳入66例可评估63例,中位随访632天,CMV再激活累积发生率为36.7%,1年无病生存率82.5%、总生存率92.1%。与102例接受传统固定剂量ATG(累积10 mg/kg)的历史对照相比,靶向给药组CMV再激活(36.7% vs 70.8%,P<.001)、EBV再激活(58.7% vs 76.0%,P=.024)更低,CD4+ T细胞重建(76.8% vs 54.1%,P=.040)更高。
要点
- ATG靶向给药组CMV再激活累积发生率为36.7%,历史对照组为70.8%(P<.001)。
- ATG靶向给药组EBV再激活累积发生率为58.7%,历史对照组为76.0%(P=.024)。
- 靶向给药组+100天CD4+ T细胞重建为76.8%,历史对照组为54.1%(P=.040)。
核心结论
- ATG靶向给药策略降低了单倍体相合外周血干细胞移植后的CMV/EBV再激活并改善了生存,且未增加GVHD。
- 这些优势可能与免疫重建加速有关。
研究设计与样本
- 单臂2期试验,评估成人非体外去除单倍体相合外周血干细胞移植中基于ATG浓度监测的靶向给药策略的安全性和有效性。
- 2020年12月至2022年1月共入组66例单倍体相合外周血干细胞移植患者,其中63例可评估,中位随访632天。
- 历史对照为102例接受传统固定ATG剂量(累积10 mg/kg)的单倍体相合外周血干细胞移植患者。
主要发现
- CMV再激活累积发生率为36.7%,EBV再激活累积发生率为58.7%。
- 1年无病生存率为82.5%,总生存率为92.1%,+100天CD4+ T细胞重建为76.8%。
- 最常见的严重方案相关毒性(>3级)为感染(51.5%)和胃肠道毒性(25.5%)。
- 历史对照结局劣于2期试验队列:CMV再激活70.8%(P<.001),EBV再激活76.0%(P=.024),CD4+ T细胞重建54.1%(P=.040)。
关键数值与推荐
- ATG在预处理期间给药4天(-5天至-2天),-3天和-2天的ATG剂量按本研究的给药策略调整以达到最佳ATG暴露。
- 主要终点为+180天CMV再激活。
- 传统固定ATG剂量为累积10 mg/kg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-thymocyte globulin (ATG) is widely used in allogeneic hematopoietic stem cell transplantation to prevent severe graft-versus-host disease (GVHD) and graft failure. However, overexposure to ATG may increase cytomegalovirus (CMV), Epstein-Barr virus (EBV) reactivation, non-relapse mortality, and disease recurrence. To investigate the optimal dosing of ATG, we established a targeted dosing strategy based on ATG concentration monitoring for haploidentical peripheral blood stem cell transplantation (haplo-PBSCT). The aim of this phase 2 trial is to evaluate the safety and efficacy of the ATG-targeted dosing strategy in adult unmanipulated haplo-PBSCT. ATG was administered for 4 days (-5 days to -2 days) during conditioning. The ATG doses on -3 days and -2 days were adjusted by our dosing strategy to achieve the optimal ATG exposure. The primary endpoint was CMV reactivation on +180 days. Between December 2020 and January 2022, 66 haplo-PBSCT patients were enrolled and 63 of them were evaluable with a median follow-up of 632 days. The cumulative incidence of CMV reactivation was 36.7% and that of EBV was 58.7%. The 1-year disease-free survival was 82.5%, overall survival was 92.1%, and CD4+ T-cell reconstruction on +100 days was 76.8%. The most common severe regimen-associated toxicities (> grade 3) were infections (51.5%) and gastrointestinal toxicity (25.5%). A total of 102 haplo-PBSCT patients who received the conventional fixed ATG dose (cumulative 10 mg/kg) comprised historical control. The outcomes in historical control were inferior to those of phase 2 trial cohort (CMV reactivation: 70.8%, p < .001; EBV reactivation: 76.0%, p = .024; CD4 + T-cell reconstruction: 54.1%, p = .040). In conclusion, ATG-targeted dosing strategy reduced CMV/EBV reactivation and improved survival without increasing GVHD after haplo-PBSCT. These advantages may be associated with accelerated immune reconstitution.
引用
- Wang H, Wang N, Wang L, et al. Targeted dosing of anti-thymocyte globulin in adult unmanipulated haploidentical peripheral blood stem cell transplantation: A single-arm, phase 2 trial. Am J Hematol. 2023. PMID: 37706580. doi:10.1002/ajh.27068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。